Skip to content

Biosynex Pharma Benelux

Active Private limited companyfounded 2022active for 4 yearsBolwerklaan 21, 1210 Saint-Josse-ten-NoodeKBO/BCE: BE 0787.324.947 subsidiary of

Lifetime

4 annual accounts with figures on one time axis
peak of €644,860 in 2022
€259,103▲ 22.2%
lowest -€764,493 in 2023
-€678,477▲ €36,388
peak of €3.9m in 2022
€1.7m▼ 28.5%
€1.2m▲ 17.4%
peak of 7.2 FTE in 2025
7.2 FTE▲ 10.8%
Board1 name since 2022
1 director
Owners
consolidates
Documentsfilings and deeds
22-06-202639 days before the deadline
2025abbreviated format
Gross margin from €211,995 to €259,103Loss of €678,477Staff from 6.5 FTE to 7.2 FTEEquity from €2.4m to €1.7mDebts from €1.1m to €1.2mCash from €166,147 to €65,498

Key points

from the 2025 annual accounts

Equity

€1.7m from €3.9m in 2022

Equity fell by 56% in 3 years.

Losses

-€2.2m in three years
-764,4932023-714,8642024-678,4772025

Every financial year from 2023 to 2025 closed with a loss. 2023 was the heaviest.

Turnover

≈ €410,000 estimated

The accounts state no turnover.

Staff

8 employees on 31-12-2025
542023322024112025

In 2025, 1 employee joined and 1 left.

Position in the sector

-€678,477

Lower net result than 95% of companies in head offices and management consultancy. Sector median €43,495 · 10,642 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 3,235 companies had the same profile as Biosynex Pharma Benelux has now. Each dot stands for 9 companies, two years later.

87.4%
were still trading
8.9%
stopped another way
3.3%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a loss of 10% of the balance sheet or more

Another 0.3% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 3,235 companies, not a prediction for Biosynex Pharma Benelux. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, , since 15-06-2022
  • consolidatesannual accounts 2025
Board & ownership

Recent changes

New establishment in Wavre Avenue Sabin 14
Incorporation Founding capital of €3,500,000, 35,000 shares · Founded by · appointed as director · published on 20-06-2022 · Gazette deed
First establishment Bolwerklaan 21, Saint-Josse-ten-Noode
All 8 events

Comparable companies

same main activity, similar in size and age
Company
Biosynex Pharma Benelux Saint-Josse-ten-Noode €2.9m €259,103 57.8% 7.2
AMA European Consulting Forest €1.7m €237,151 25.7% 3.9
Triple Helix G-PUR Antwerp €1.6m €213,370 17.1% 4.4
MONS GRAND PLACE Seneffe €2.3m €239,303 -2.4% 3.1
TRILLIGENT Brussels €1.3m €257,109 -21.8% 3.8
MyMove Brussels €1.2m €178,829 39.6% 5.9
TEKsystems Global Services (Belgium) Brussels €1.9m €603,687 -29.3% 4.4

These companies have the same main activity as Biosynex Pharma Benelux: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €1.2m and €2.3m, founded between 2020 and 2023.

Official details

Source: KBO
Status
Active since 16-06-2022Normal situation
Registered office
150 active companies are registered at this address16 started in the 12 months before. Source: KBO register, as of 18 November 2026.
Activity
Business and other management consultancyNACE 70200and 1 other
Joint committee
207White-collar workers in the chemical industry · annual accounts 2025
Establishment units
2.336.539.7601210 Saint-Josse-ten-Noode, since 16-06-2022
2.336.539.8591300 Wavre, since 10-10-2022
Financial year end
31 December
Peppol
Reachable
Company details

Annual accounts 2025

€2.9m▼ 14.4%
Employeeson 31-12-2025
8=
Filing
Filed on 22-06-2026, 39 days before the end of the filing period
Financials

Insights on Biosynex Pharma Benelux

Biosynex Pharma Benelux files the abbreviated format. That format states no turnover. The gross margin fell from €644,860 in 2022 to €259,103 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Biosynex Pharma Benelux

What is the company number of Biosynex Pharma Benelux?
The company number of Biosynex Pharma Benelux is 0787.324.947. The VAT number is the same number with BE in front: BE 0787.324.947.
Where is Biosynex Pharma Benelux based?
The registered office is at Bolwerklaan 21, 1210 Saint-Josse-ten-Noode.Company details
What does Biosynex Pharma Benelux do?
According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
What is the legal form of Biosynex Pharma Benelux?
Biosynex Pharma Benelux is a private limited company (BV).
When was Biosynex Pharma Benelux founded?
Biosynex Pharma Benelux was founded on 16-06-2022.
Is Biosynex Pharma Benelux still active?
Yes, Biosynex Pharma Benelux is an active enterprise in the KBO register.
How many employees does Biosynex Pharma Benelux have?
Biosynex Pharma Benelux had an average of 7.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does Biosynex Pharma Benelux fall under?
In its 2025 annual accounts, Biosynex Pharma Benelux states joint committee 207 (White-collar workers in the chemical industry).
What is the turnover of Biosynex Pharma Benelux?
The turnover in financial year 2025 is ≈ €410,000. This figure is estimated from the gross margin of €259,103 and 73 comparable companies (NACE 70200). It probably lies between €310,000 and €720,000. In financial year 2023 turnover was €1.4m.
Is Biosynex Pharma Benelux profitable?
In financial year 2025, Biosynex Pharma Benelux made a loss of €678,477.
Where can I find the annual accounts of Biosynex Pharma Benelux?
Biosynex Pharma Benelux filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Biosynex Pharma Benelux due?
Biosynex Pharma Benelux must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.